Back
ATX
Amplia Therapeutics Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 2.38%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The firm is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The firm's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The firm's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
📈 Performance
Price History
-5.06%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.15
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ATX
5
📊 Total Capital Earnings
$6K
🔃 Average investment frequency
25 weeks
💵 Average investment amount
$1,415
⏰ Last time a customer invested in ATX
2 days
ATX investor breakdown
💵 Income of investors
More than 200k
40%
150k - 200k
20%
100k - 150k
20%
50k - 100k
Less than 50k
20%
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
60%
Male
40%
Pearlers who invest in ATX also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
9.33%
📊 Share price
$110.41 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
NDQ
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
21.47%
📊 Share price
$53.23 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
🇺🇸 UNITED STATES
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
17.41%
📊 Share price
$147.54 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
IVV
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
22.57%
📊 Share price
$65.86 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 297.69m in AUM and 209 holdings. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index).
🙌 Performance (5Yr p.a)
11.35%
📊 Share price
$29.28 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
Want more shares? Try these...
